Clinical Trial Update: A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) [Phase 2]

View source ↗

Summary

This update reports the termination of a Phase IIb trial evaluating low-dose intravenous cinaciguat in patients with acute decompensated heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure

Drugs mentioned

• Cinaciguat (cinaciguat)

Snippet

Sponsor: Bayer | Conditions: Acute Heart Failure | Phase 2 | Status: TERMINATED